Oramed Pharmaceuticals Dividend
Dividend criteria checks 0/6
Oramed Pharmaceuticals does not have a record of paying a dividend.
Key information
n/a
Dividend yield
n/a
Payout ratio
| Industry average yield | 2.3% |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Earnings per share | US$0.14 |
| Dividend yield forecast in 3Y | n/a |
Recent dividend updates
No updates
Recent updates
Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation
Aug 24
Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans
May 03Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth
Dec 22Oramed: Oral Insulin For Type 2 Diabetes May Become A Reality
Sep 21Oramed to hand Korean rights for insulin capsule
Sep 09Oramed to report early-stage trial data for oral COVID-19 shot in 3Q
Jul 07Is Oramed Pharmaceuticals (NASDAQ:ORMP) In A Good Position To Invest In Growth?
Jun 12Oramed And Oral Insulin: Can This Small Company Really Do It?
Apr 14Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth
Feb 23Oramed And The Hurdles Of Developing Oral Insulin
Dec 23Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation
Nov 02Oramed: Prospects Still Remain Despite Merck-Ridgeback's Progress
Oct 04We Think Shareholders Will Probably Be Generous With Oramed Pharmaceuticals Inc.'s (NASDAQ:ORMP) CEO Compensation
Aug 24Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans
Jul 21Oramed reaches 50% enrollment in late-stage oral insulin study
Jun 08Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans
Apr 06The Oramed Pharmaceuticals (NASDAQ:ORMP) Share Price Is Up 110% And Shareholders Are Boasting About It
Feb 12
Oramed Pharmaceuticals EPS beats by $0.42, revenue in-line
Jan 14Why Oramed Pharmaceuticals' (NASDAQ:ORMP) CEO Pay Matters
Jan 08Oramed's obesity drug candidate shows decrease in glucose levels
Dec 23We Think Oramed Pharmaceuticals (NASDAQ:ORMP) Can Afford To Drive Business Growth
Dec 04Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if ORMP's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ORMP's dividend payments have been increasing.
Dividend Yield vs Market
| Oramed Pharmaceuticals Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (ORMP) | n/a |
| Market Bottom 25% (US) | 1.6% |
| Market Top 25% (US) | 4.8% |
| Industry Average (Pharmaceuticals) | 2.3% |
| Analyst forecast in 3 Years (ORMP) | n/a |
Notable Dividend: Unable to evaluate ORMP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ORMP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate ORMP's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ORMP has not reported any payouts.